Compounds > prostaglandin d3
Page last updated: 2024-11-10

prostaglandin d3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prostaglandin D3: has effect on neural transmission [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

prostaglandin D3 : A member of the class of prostaglandins D that is prosta-5,13,17-trien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,13E,15S,17Z-stereoisomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5282260
CHEBI ID34939
MeSH IDM0088119

Synonyms (22)

Synonym
CHEBI:34939
(5z,13e,15s,17z)-9alpha,15-dihydroxy-11-oxoprosta-5,13,17-trien-1-oic acid
(5z)-7-[(1r,2r,5s)-5-hydroxy-2-[(1e,3s,5z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoic acid
895xe61e0i ,
unii-895xe61e0i
(5z,9alpha,13e,15,17z)-9,15-dihydroxy-11-oxoprosta-5,13,17-trien-1-oic acid
prosta-5,13,17-trien-1-oic acid, 9,15-dihydroxy-11-oxo-, (5z,9alpha,13e,15,17z)-
prostaglandin d3
71902-47-1
9s,15s-dihydroxy-11-oxo-5z,13e,17z-prostatrienoic acid
pgd3
LMFA03010142
(z)-7-[(1r,2r,5s)-5-hydroxy-2-[(1e,3s,5z)-3-hydroxyocta-1,5-dienyl]-3-oxocyclopentyl]hept-5-enoic acid
prosta-5,13,17-trien-1-oicacid, 9,15-dihydroxy-11-oxo-, (5z,9a,13e,15s,17z)-
(5z,9.alpha.,13e,15s,17z)-9,15-dihydroxy-11-oxoprosta-5,13,17-trien-1-oic acid
prosta-5,13,17-trien-1-oicacid,9,15-dihydroxy-11-oxo-,(5z,9a,13e,15s,17z)-
9s,15s-dihydroxy-11-oxo-5z,13e,17z-prostatrienoate
Q28529673
sr-01000946835
SR-01000946835-1
CS-0059566
HY-113444
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins D
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.14 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
eicosapentaenoic acid
icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.		1.9610icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
prostaglandin d2
Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).		2.3620prostaglandins Dhuman metabolite;
mouse metabolite
alprostadil
[no description available]		2.3720prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
prostaglandin e3
prostaglandin E3: Structure		2.3720prostaglandins Ehuman metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9510
Intraocular Pressure
The pressure of the fluids in the eye.		01.9610